Can Insilico Medicine’s rentosertib slow FVC decline in Phase 3 IPF study?
Insilico Medicine starts Phase 3 testing of rentosertib in IPF, putting its AI-discovered TNIK inhibitor through a decisive 52-week trial.
Pharma & Biotech